Similar articles for PMID: 31486929

Year	Number of Results
2007	1
2008	2
2012	1
2013	3
2014	3
2015	14
2016	22
2017	14
2018	28
2019	25
2020	25
2021	28
2022	15
2023	3
2024	0

1

Maneuvering Clinical Pathways for Ulcerative Colitis.

Johnson CM, Linzay CD, Dassopoulos T. Johnson CM, et al. Curr Gastroenterol Rep. 2019 Sep 5;21(10):52. doi: 10.1007/s11894-019-0716-3. Curr Gastroenterol Rep. 2019. PMID: 31486929 Review.

2

Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis.

Dalal RS, Goksel B, Hamilton MJ. Dalal RS, et al. Dig Dis Sci. 2023 May;68(5):1709-1713. doi: 10.1007/s10620-023-07866-9. Epub 2023 Mar 17. Dig Dis Sci. 2023. PMID: 36929242 No abstract available.

3

Tofacitinib in Ulcerative Colitis-evolving Efficacy and Safety.

Tiwari A, Ashraf A, Bharali P. Tiwari A, et al. J Clin Gastroenterol. 2023 Apr 1;57(4):429. doi: 10.1097/MCG.0000000000001823. J Clin Gastroenterol. 2023. PMID: 36728526 No abstract available.

4

Review article: guide to tofacitinib dosing in patients with ulcerative colitis.

Irving PM, Leung Y, Dubinsky MC. Irving PM, et al. Aliment Pharmacol Ther. 2022 Oct;56(7):1131-1145. doi: 10.1111/apt.17185. Epub 2022 Aug 22. Aliment Pharmacol Ther. 2022. PMID: 35993338 Free PMC article. Review.

5

Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.

Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Chiorean MV, et al. BMC Gastroenterol. 2022 Jul 26;22(1):356. doi: 10.1186/s12876-022-02298-7. BMC Gastroenterol. 2022. PMID: 35883049 Free PMC article. No abstract available.

6

Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective.

Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Mishra S, et al. Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):737-752. doi: 10.1080/17474124.2022.2106216. Epub 2022 Aug 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35875997 Review.

7

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database.

Seo GH, Jung SH. Seo GH, et al. J Korean Med Sci. 2022 Apr 25;37(16):e123. doi: 10.3346/jkms.2022.37.e123. J Korean Med Sci. 2022. PMID: 35470598 Free PMC article.

8

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.

Cohen NA, Choi D, Choden T, Cleveland NK, Cohen RD, Rubin DT. Cohen NA, et al. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2407-2409.e2. doi: 10.1016/j.cgh.2022.03.035. Epub 2022 Apr 2. Clin Gastroenterol Hepatol. 2023. PMID: 35381385 Free PMC article.

9

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.

Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Panaccione R, et al. Aliment Pharmacol Ther. 2022 Jun;55(12):1534-1544. doi: 10.1111/apt.16848. Epub 2022 Mar 5. Aliment Pharmacol Ther. 2022. PMID: 35246988 Free PMC article.

10

Editorial: real-world safety of tofacitinib in ulcerative colitis.

Taxonera C. Taxonera C. Aliment Pharmacol Ther. 2022 Feb;55(3):368-369. doi: 10.1111/apt.16740. Aliment Pharmacol Ther. 2022. PMID: 35040163 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

161 results

Results by year